Anti-IL-6 for GVHD prophylaxis had no improvement in long term-survival.Addition of etanercept (TNF inhibitor) to a standard GVHD prophylaxis regimen delayed development of aGVHD but had no favorable impact on cGVHD. Here, TNF is linked to graft versus host disease.